Opiant Pharmaceuticals said that it has discontinued development of OPNT001 naloxone nasal spray for the treatment of bulimia nervosa (BN) after a Phase 2 study failed to meet its primary endpoint. The company had announced the initiation of the study in March 2017.
Opiant CEO Roger Crystal commented, “Based on these results, Opiant will not allocate further resources to the development of OPNT001 for the treatment of BN, allowing us to invest more in our pipeline. The company’s focus for 2019 remains on conducting the pivotal trial for OPNT003, nasal nalmefene for opioid overdose, preparing to enroll patients into a Phase 2 study for OPNT002, nasal naltrexone, for the treatment of alcohol use disorder and progressing the development of OPNT004, drinabant, for acute cannabinoid overdose. We wish to express our gratitude to the investigators, as well as the patients and their families, for their support and participation in the BN study.”
Read the Opiant Pharmaceuticals press release.
